Meeting with ViiV/GSK

Meeting with ViiV/GSK

During the meeting of UCAB members and state bodies’ representatives for the first time an agreement on the inclusion of patients into the group under the Ministry of Health of Ukraine (MoH) responsible for the list of drugs for procurement was reached. The meeting was held within the training «ART procurement in Ukraine: state bodies procedures and the Global Fund to Fight AIDS, Tuberculosis and Malaria model». Furthermore, the participation of patient organizations in the group of monitoring and field-specific support of state programs was positively negotiated.

«In case we have a vote in the group, which identifies the list of drugs for procurement, and influence the process of its selection — the new era of patient-government relations will begin, which will move state procurement process towards international standards, based on transparency, — says Dmytro Sherembey, UCAB Head. — We are against decentralization of state procurement of ARVs next year, as this act can put 10-years treatment program under the threat. We predict that decentralization will lead to multiple treatment interruptions, unlimited corruption options and treatment standards ignorance. By patients involvement we will make an attempt to arrange timely procurement and supply management of essential medicines in order to prevent the situation that happened this year — when they start drugs distribution for 2011 in November only».

Moreover, MoH representatives’ participation in the training gave a possibility for patients to raise the issue of WHO prequalification measure inclusion into procurement concept paper for 2013. «We advocate for WHO prequalification of drugs, procured by MoH since 2007. Previous MoH management reproached us that such measure for state procurement automatically discriminates national manufacturers. But this is pure manipulation — WHO prequalification procedure can be provided for anyone, as this process is free of charge. After all, present MoH management is ready to cooperate on this issue, and we will work together in order this measure is included into procurement documents for 2013» — claims Konstantin Lezhentsev, UCAB expert.

ViiV Healthcare representatives announced about the possibility of further price reduction for their products, for Abakavir in particular. It may happen in the coming years, taking into account patent protection status of original drugs. Such an act will let to considerably increase the number of patients on treatment.

Clinical trials results of new ARV drugs and the issues of safe Abakavir use were also discussed during the meeting. The patients and the company agreed upon cooperation between UCAB members and ViiV Healthcare representatives in order to provide access to hypersensitivity tests for Ukrainian patients. This particular test is considered to be a critical point on the way to prevent side effects and increase life quality of patients on treatment.

[dt_quote type=”blockquote” font_size=”normal” animation=”none” background=”plain”]Additional information:
ViiV Healthcare is an international pharmaceutical company, specialized on HIV drugs development and production, represented by GlaxoSmithKline Pharmaceuticals Ukraine in Ukraine.[/dt_quote]

[gview file=”/2011/11/UCAB_News_11_11_11-engl.doc” save=”1″]

Leave a Reply

Your email address will not be published. Required fields are marked *